Media Summary: The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker "We're starting this because we believe it could work,"
The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker "We're starting this because we believe it could work,"
NBC News' Tom Llamas
Eli Lilly
Eli Lilly
Eli Lilly
Eli Lilly
Eli Lilly CEO
CNBC's Angelica Peebles and
Eli Lilly
CNBC's Meg Tirrell and David Ricks,
The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker
In November,
"We're starting this because we believe it could work,"
Eli Lilly CEO
